Clinical Trial: Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Baxalta US Inc.
Dates:
Date Received: November 2, 2016
Date Started: November 2016
Date Completion: December 2021
Last Updated: November 21, 2016
Last Verified: November 2016